Impax Laboratories on Tuesday said it had agreed to pay $145 million to resolve antitrust class claims that the drugmaker illegally schemed with Endo International Plc to delay launching a generic version of its Opana ER opioid painkiller.
The settlement resolving allegations brought by plaintiff drug distributors Value Drug Co and Meijer Inc came just weeks after a Chicago federal court jury rejected claims that Endo violated federal antitrust laws.
Impax, which had been a defendant, reached a deal in principle as the trial was set to start but did not publicly reveal the settlement’s terms then.
The preliminary deal is subject to review by U.S. District Judge Harry Leinenweber in Chicago.
Class members will receive “substantial cash settlement payments,” the plaintiffs’ attorneys said in their Tuesday filing seeking court approval of the deal, “while putting the litigation against Impax to rest and avoiding the inherent risks of jury trial (as demonstrated by the verdict in favor of Endo) and potential appeals.”
Lead class attorneys, including Andrew Curley of Berger Montague and Bruce Gerstein of Garwin Gerstein & Fisher, on Wednesday did not immediately respond to a message seeking comment.
A lawyer for Impax, Devora Allon of Kirkland & Ellis, and a representative from the company, now owned by New Jersey-based Amneal Pharmaceuticals Inc, did not immediately respond to messages seeking comment.
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Canadian Breadmakers Settle Price-Fixing Lawsuit
Jul 25, 2024 by
CPI
EssilorLuxottica Open to Meta as Shareholder, Says CEO Francesco Milleri
Jul 25, 2024 by
CPI
California Supreme Court Upholds Proposition 22, Securing Independent Contractor Status for Uber and Lyft Drivers
Jul 25, 2024 by
CPI
Paramount Global Investor Sues to Block Skydance Media Merger
Jul 25, 2024 by
CPI
Software Vendors Win Class Action Status in Antitrust Case Against CDK Global
Jul 25, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – International Trade & Antitrust
Jul 26, 2024 by
CPI
What is Wrong with the WTO Discipline on Subsidies?
Jul 26, 2024 by
CPI
The Abiding Tension Between Trade Remedy Law and Antitrust
Jul 26, 2024 by
CPI
Trade and Antitrust: An End to Isolationism
Jul 26, 2024 by
CPI
International Trade Law and Domestic Regulation of Generative Artificial Intelligence: Divergent Approaches?
Jul 26, 2024 by
CPI